ALMSAlumis Inc.
$7.17+72% 1Y
$7.17
$3.9552 weeks$30.07
ALMS in its own filings
Nothing in ALMS's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
63
Events found in the filings · across 242 filings · the record starts in 2024
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 1, 2026
Most recent filing · Form 8-K
- Record starts
- May 8, 2024
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- SEC comment-letter activity15 occurrences
- 2025-08-15
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026On September 1, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE).” The Company is also filing slides presented by the Company at a webcast regarding the LUMUS Phase 2b topline results …Other event · Form 8-K
- Aug 13, 2026Alumis Reports Second Quarter 2026 Financial Results and.Earnings release · press release
- Aug 10, 2026On August 10, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies”Other event · Form 8-K
- Jun 29, 2026On June 29, 2026, Alumis Inc. (the “Company”) updated its corporate presentation for use in meetings with investors, analysts, and others.Other event · Form 8-K
- May 14, 2026Alumis Reports First Quarter 2026 Financial Results and.Earnings release · press release
- Mar 30, 2026On March 28, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis”Other event · Form 8-K
- Mar 19, 2026Alumis Reports Year End 2025 Financial Results and Highlights.Earnings release · press release
- Jan 9, 2026On January 7, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a …Earnings release · Form 8-K
- Jan 6, 2026On January 6, 2026, Alumis Inc. (the “Company” or “Alumis”) issued a press release titled “Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program”Other event · Form 8-K
- Jan 2, 2026On January 2, 2026, Alumis Inc. (the “Company”) and its wholly-owned subsidiary Acelyrin, Inc. (“Acelyrin”) issued a Notice of Material Breach and Notification of Claim for Indemnification to Climb Bio, Inc. (“Climb Bio”), after Climb Bio knowingly and willfully refused to pay a $3,000,000 Development Milestone …Other event · Form 8-K
- Nov 13, 2025Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Biotechnology
The closest names by size in the same industry